Chronic pain caused by the nerve damage of type 2 diabetes, surgical amputation, chemotherapy and other conditions is especially intractable because it resists painkilling medications.
But in a study on mice, a Duke University team has shown that injections of stem cells from bone marrow might be able to relieve this type of neuropathic pain. The researchers say their findings, which appear July 13 in the Journal of Clinical Investigation, may also advance cell-based therapies in chronic pain conditions, lower back pain and spinal cord injuries.
The team used a type of stem cell known as bone marrow stromal cells (BMSCs), which are known to produce an array of healing factors and can be coaxed into forming most other types of cells in the body.
Stromal cells are already being tested in small-scale clinical studies of people with inflammatory bowel disease, heart damage and stroke. They have also shown promise for treating pain. However, it’s not clear how they work.
“Based on these new results, we have the know-how and we can further engineer and improve the cells to maximize their beneficial effects,” said Ru-Rong Ji, professor of anesthesiology and neurobiology in the Duke School of Medicine.
In his team’s study, the researchers used stromal cells to treat mice with pain caused by nerve damage. They delivered the cells by a lumbar puncture, infusing them into the fluid that bathes the spinal cord.
Mice treated with the bone marrow stromal cells were much less sensitive to painful stimuli after their nerve injury compared with the untreated mice, the researchers found.
“This analgesic effect was amazing,” Ji said. “Normally, if you give an analgesic, you see pain relief for a few hours, at most a few days. But with bone marrow stem cells, after a single injection we saw pain relief over four to five weeks.”
Pictures of the animals’ spinal cords showed that the injected stem cells had set up shop alongside the nerve cells in the spinal cord.
To understand how the stem cells alleviated pain, the researchers measured levels of anti-inflammatory molecules that had been previously linked to pain, finding that one in particular, TGF-?1, was present in higher amounts in the spinal fluid of the stem cell-treated animals compared with the untreated animals.
TGF-?1 is a protein that is typically secreted by immune cells and is common throughout the body. Research has shown that people with chronic pain have too little TGF-?1, Ji said.
In the new study, chemically neutralizing TGF-?1 reversed the pain-killing benefit of the BMSCs, suggesting that the secretion of this protein was a major reason why the cells helped with pain. Injecting TGF-?1 directly into spinal cord fluid provides relief too, but only for a few hours, Ji said.
By contrast, bone marrow stromal cells stay on site for as much as three months after the infusion, the scientists found. This is the right length of time, Ji said, because if the stem cells stayed permanently there could be risk of them becoming cancerous.
Importantly, BMSCs also migrate to the site of injury. That’s because a molecule emitted from the injured nerve cells called CXCL12 — which has also previously been linked to neuropathic pain — acts as a homing signal of sorts, attracting the stem cells.
The Latest on: Neuropathic pain
via Google News
The Latest on: Neuropathic pain
- Ask Yourself – If You Didn’t Have Knee Pain, Would You Even Be Looking for a Doctor?on October 13, 2021 at 1:15 pm
If you are a candidate for AROmotion's FDA-approved micro-procedure, it can stop the nerve pain, promote healing of the cavities, and save your natural joint.
- Cannabis Oil Effective for UK Chronic Pain Patientson October 11, 2021 at 7:01 am
Medical cannabis has been legal in the United Kingdom since 2018, but we’re only now getting the first evidence on the effectiveness of cannabis oil for UK chronic pain patients. One hundred ten ...
- Idorsia's Fabry med did what executives were expecting—it just didn’t relieve the disease's hallmark burning painon October 11, 2021 at 5:39 am
Idorsia’s Fabry disease therapy “did exactly what we were expecting,” according to one executive—except relieve neuropathic pain. That means lucerastat failed in a phase 3 clinical trial in adult ...
- Sickle Cell Disease Pain Management: New Funding Opportunities for Clinical Research are Coming Soonon October 7, 2021 at 3:02 pm
Initiative has released notices of two upcoming funding opportunity announcements (FOAs) to support large-scale clinical trials on sickle cell disease (SCD) pain management. The National Center for Co ...
- Pain Management Devices Market is Growing at a CAGR of 7.89% and will reach USD 6.14 Billion by 2026, Asserts DelveInsighton October 7, 2021 at 10:30 am
DelveInsight published a new report on "Pain Management Devices Market & Competitive Landscape," proffering in-depth market understanding for the Pain Management Devices market, further benefiting the ...
- Global Neuropathic Pain Therapeutics Market 2021 Trend and Opportunities, PESTEL Analysis, CAGR and Value Chain Study to 2027on October 6, 2021 at 4:40 pm
Global Neuropathic Pain Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2027 is ...
- Biomarkers of Pain Could Lead to Better Therapieson October 1, 2021 at 1:46 am
Researchers have mapped the biomarkers of different types of pain to categorise and better treat them in the future.
- NIH/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain Stateson September 30, 2021 at 8:00 am
The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), has awarded AnaBios a $1,734,409 Small Business Innovation Research (SBIR) grant ...
- Neuropathic Painon September 29, 2021 at 5:00 pm
These bundles of nerve fibers can be damaged in the event of blunt or sharp force trauma due to accidents, ... Three decades-old antibiotics administered together can block a type of pain ...
- Pathophysiological Mechanisms of Neuropathic Painon September 29, 2021 at 5:00 pm
At the bedside examination, neuropathic pain can been distinguished from spontaneous pain, (i.e., stimulus independent) and provoked pain.  Spontaneous pain can have several different qualities.
via Bing News